Global Prostate Cancer Therapeutic Market to 2020

Publisher Name :
Date: 11-May-2015
No. of pages: 76

Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some hindrances as well such as the high cost of prostate cancer drugs, low success rate of clinical trials and side effects of treatments among others.

Global Prostate Cancer - Key Therapies Analysis: The global market for prostate cancer therapeutics is increasing, driven primarily by the growth in the hormonal therapy markets. Chemotherapy was the second leading therapy for prostate cancer in 2014. However, growth in the targeted therapy is predicted to push chemotherapy back at the third position, while immunotherapy for prostate cancer stands at the last position in the prostate cancer therapeutics market.

Prostate Cancer Drugs Analysis: Zytiga leads the prostate cancer drugs market in 2014. Zytiga is facing stiff competition from Xtandi drugs which is expected to replace Zytiga as the leading prostate cancer drugs. In prostate cancer drugs market, Leuplin and Zoladex stands at the third and fourth position in 2014. The market share of both Leuplin and Zoladex is likely to plunge during the forecasting period. Lupron is standing at the fifth position. Bayer's targeted therapy drugs Xofigo is also rapidly catching up the market due to advantages such as increase in the overall survival and progression free survival with benign side effects profile.

Global Prostate Cancer Therapeutics Market to 2020 is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market.  

The 4 Prostate Cancer Therapy Market covered in the report are as follows:


  • Hormonal Therapy

  • Chemotherapy

  • Immunotherapy

  • Targeted Therapy


The above 4 Therapy has been further analyzed in terms of drugs sales and forecast (2011 - 2020):

1. Global Prostate Cancer - Hormonal Therapy Drugs Market


  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists - Zytiga, Gonax

  • Luteinizing Hormone-Releasing Hormone (LHRH) Analogs - Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Leuplin

  • Anti-Androgens - Casodex, Xtandi or MDV3100, Xtandi US or MDV3100


2. Global Prostate Cancer - Chemotherapy Drugs Market


  • Taxotere

  • Jevtana


3. Global Prostate Cancer - Immunotherapy Drugs Market


  • Provenge


4. Global Prostate Cancer - Targeted Therapy Drugs Market


  • Xofigo or Alpharadin


Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Global Prostate Cancer Therapeutic Market to 2020

Table of Contents

1. Executive Summary

2. Global Prostate Cancer Therapeutics Market

3. Global Prostate Cancer Incidence

4. Global Prostate Cancer Therapeutics Market Share & Forecast (2011 - 2020)
4.1 Global Prostate Cancer - Therapy Market Share
4.2 Global Prostate Cancer - Drugs Market Share

5. Global Prostate Cancer Therapy Market & Forecast (2011 - 2020)
5.1 Global Prostate Cancer Hormonal Therapy Market & Forecast
5.2 Global Prostate Cancer Chemotherapy Market & Forecast
5.3 Global Prostate Cancer Immunotherapy Market & Forecast
5.4 Global Prostate Cancer Targeted Therapy Market & Forecast

6. Global Prostate Cancer - Hormonal Therapy Drugs Sales & Forecast To 2020
6.1 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
6.1.1 Zytiga
6.1.2 Gonax/ Firmagon
6.2 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
6.2.1 Lupron
6.2.2 Zoladex
6.2.3 Decapeptyl
6.2.4 Eligard
6.2.5 Vantas
6.2.6 Leuplin
6.3 Anti-Androgens
6.3.1 Casodex
6.3.2 Xtandi or MDV3100
6.3.3 Xtandi US or MDV3100

7. Global Prostate Cancer - Chemotherapy Drugs Market
7.1 Taxotere
7.2 Jevtana

8. Global Prostate Cancer - Immunotherapy Drugs Market
8.1 Provenge

9. Global Prostate Cancer - Targeted Therapy Drugs Market
9.1 Xofigo or Alpharadin

10. Global Prostate Cancer Market - Driving Factors
10.1 Innovative Drugs Driving the Market
10.2 Advancement in Oncology Therapeutic Area
10.3 Developments in Genomics & Proteomics

11. Global Prostate Cancer Market - Challenges
11.1 High Cost of Prostate Cancer Drugs
11.2 Adverse Events of Treatment
11.3 Low Success Rate in Clinical Testing For Oncology Drugs

List of Figures

Figure 2-1: Global - Prostate Cancer Therapeutics Market (Million US$), 2010 - 2014
Figure 2-2: Global - Forecast for Prostate Cancer Therapeutics Market (Million US$), 2015 - 2020
Figure 3-1: Global - Prostate Cancer Incidence (Number), 2007 - 2014
Figure 3-2: Global - Forecast for Prostate Cancer Incidence (Number), 2015 - 2020
Figure 5-1: Global Prostate Cancer - Hormonal Therapy Market (Million US$), 2011 - 2014
Figure 5-2: Global Prostate Cancer - Forecast for Hormonal Therapy Market (Million US$), 2015 - 2020
Figure 5-3: Global Prostate Cancer - Chemotherapy Market (Million US$), 2011 - 2014
Figure 5-4: Global Prostate Cancer - Forecast for Chemotherapy Market (Million US$), 2015 - 2020
Figure 5-5: Global Prostate Cancer - Immunotherapy Market (Million US$), 2011 - 2014
Figure 5-6: Global Prostate Cancer - Forecast for Immunotherapy Market (Million US$), 2015 - 2020
Figure 5-7: Global Prostate Cancer - Targeted Therapy Market (Million US$), 2013 - 2014
Figure 5-8: Global Prostate Cancer - Forecast for Targeted Therapy Market (Million US$), 2015 - 2020
Figure 6-1: Global - Zytiga Drugs Sales (Million US$), 2011 - 2014
Figure 6-2: Global - Forecast for Zytiga Drugs Sales (Million US$), 2015 - 2020
Figure 6-3: Global - Gonax/ Firmagon Drugs Sales (Million US$), 2012 - 2014
Figure 6-4: Global - Forecast for Gonax Drugs Sales (Million US$), 2015 - 2020
Figure 6-5: Global - Lupron Drugs Sales (Million US$), 2009 - 2014
Figure 6-6: Global - Forecast for Lupron Drugs Sales (Million US$), 2015 - 2020
Figure 6-7: Global - Zoladex Drugs Sales (Million US$), 2009 - 2014
Figure 6-8: Global - Forecast for Zoladex Drugs Sales (Million US$), 2015 - 2020
Figure 6-9: Global - Decapeptyl Drugs Sales (Million US$), 2009 - 2014
Figure 6-10: Global - Forecast for Decapeptyl Drugs Sales (Million US$), 2015 - 2020
Figure 6-11: Global - Eligard Drugs Sales (Million US$), 2009 - 2014
Figure 6-12: Global - Forecast for Eligard Drugs Sales (Million US$), 2015 - 2020
Figure 6-13: Global - Vantas Drugs Sales (Million US$), 2009 - 2014
Figure 6-14: Global - Forecast for Vantas Drugs Sales (Million US$), 2015 - 2020
Figure 6-15: Global - Leuplin Drugs Sales (Million US$), 2009 - 2014
Figure 6-16: Global - Forecast for Leuplin Drugs Sales (Million US$), 2015 - 2020
Figure 6-17: Global - Casodex Drugs Sales (Million US$), 2009 - 2014
Figure 6-18: Global - Forecast for Casodex Drugs Sales (Million US$), 2015 - 2020
Figure 6-19: Global - Xtandi or MDV3100 Drugs Sales (Million US$), 2012 - 2014
Figure 6-20: Global - Forecast for Xtandi or MDV3100 Drugs Sales (Million US$), 2015 - 2020
Figure 6-21: Global - Xtandi US or MDV3100 Drugs Sales (Million US$), 2012 - 2014
Figure 6-22: Global - Forecast for Xtandi US or MDV3100 Drugs Sales (Million US$), 2015 - 2020
Figure 7-1: Global - Taxotere Drugs Sales (Million US$), 2011 - 2014
Figure 7-2: Global - Forecast for Taxotere Drugs Sales (Million US$), 2015 - 2020
Figure 7-3: Global - Jevtana Drugs Sales (Million US$), 2010 - 2014
Figure 7-4: Global - Forecast for Jevtana Drugs Sales (Million US$), 2015 - 2020
Figure 8-1: Global - Provenge Drugs Sales (Million US$), 2011 - 2014
Figure 8-2: Global - Forecast for Provenge Drugs Sales (Million US$), 2015 - 2020
Figure 9-1: Global - Xofigo or Alpharadin Drugs Sales (Million US$), 2013 - 2014
Figure 9-2: Global - Forecast for Xofigo or Alpharadin Drugs Sales (Million US$), 2015 - 2020
Figure 11-1: Therapeutic Categories - Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 - 2010

List of Tables

Table 4-1: Global - Prostate Cancer Therapy Market Share (Percent), 2011 - 2014
Table 4-2: Global - Forecast for Prostate Cancer Therapy Market Share (Percent), 2015 - 2020
Table 4-3: Global - Prostate Cancer Drugs Market Share (Percent), 2011 - 2014
Table 4-4: Global - Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 - 2020

  • Global Breast Cancer Monoclonal Antibodies Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 153
    Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Scope of the Report: This report studies the Breast Cancer Monoclonal Antibodies market status and outlook of Glo......
  • Global Immuno-Oncology Market Growth (Status and Outlook) 2018-2023
    Published: 19-Oct-2018        Price: US 3660 Onwards        Pages: 153
    Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers. Over the next five years, LPI(LP Information) projects that Immuno-Oncology will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017. In this report, LP Information studies the present scenario (with the base year bei......
  • Global Non-Hodgkin Lymphoma Therapeutics Market Size, Status and Forecast 2018-2025
    Published: 19-Oct-2018        Price: US 3900 Onwards        Pages: 95
    Non-Hodgkin lymphoma (NHL) is a condition where abnormal lymphocytes are produced in the human body. These lymphocytes do not die and keep growing and dividing within the body unless treated. NHL is generally located at lymph nodes, however, if not treated in time then it might spread to the entire lymphatic system. Factors such as demand for innovative drugs and novel technologies, FDA's approval for chronic lymphocytic leukemia therapy drugs, introduction of promising drugs such as nove......
  • Global Bladder Cancer Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 115
    The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells. Scope of the Report: This report studies the Bladder Cancer Therape......
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 218
    Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scal......
  • Essential Thrombocythemia - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 94
    Essential Thrombocythemia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H2 2018, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape. Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essen......
  • Pheochromocytoma - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 94
    Pheochromocytoma - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2018, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness o......
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 116
    Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape. Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal corte......
  • Rhabdomyosarcoma - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 307
    Rhabdomyosarcoma - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2018, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs